RUBIN’S REFLECTIONS

Follow on Twitter @IBDMD

Message to Dr. Rubin’s Patients Related to COVID-19 Boosters

Aug 13, 2021

Dear Friends and Patients, I hope this message finds you well. Please excuse the group nature of this message, but I did want to reach out with the latest update about COVID-19, and vaccinations. If you want to skip right to the booster info, scroll down to #5 below....

Tweetorial to Provide Updates on COVID-19 for Patients with IBD

Jul 30, 2021

View Twitter Thread To watch me deliver the full lecture and view the presentation, click here. I recently gave a lecture about COVID-19 and vaccination with specific information for patients with IBD. This lecture was recorded on July 21st, before the CDC issued...

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study

Apr 18, 2021

Tweetorial to Clarify the NYT Article From 15 April and Further Explain/Clarify the UK CLARITY IBD Study David T. Rubin View Twitter Thread I've previously commented about the CLARITY IBD Study (Kennedy, et al). paper in this forum, but it bears repeating and further...

SARS Vaccine and IBD Tweetorial Summary from December 1

Dec 5, 2020

SARS Vaccine and IBD Tweetorial Summary from December 1 David T. Rubin View Twitter Thread Here are my thoughts and a few updates about SARS-CoV-2 vaccines, and also about important implications for our IBD patients. Development of multiple SARS-CoV-2 vaccines in the...

Approach to Management and Interpretation of Testing Results in Patients with IBD, with Particular Attention to Restarting Therapy

Apr 21, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine As testing for SARS-CoV-2 is expanded and serologic antibody testing becomes available, we are faced with a number of different clinical scenarios. I have outlined the different situations...

Three waves of Illness from the COVID-19 Pandemic

Apr 1, 2020

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine I've been thinking about what comes next, and how can we get ahead of this, and propose the following for consideration. I believe that there will be three waves of illness from the...

Trial by Data: Chronic Disease & Data

by dtrubin | May 15, 2018 | Data, In the Press, monitoring | 0 Comments

Listen to Dr. Rubin featured on a podcast by Litmus Health, Trial by Data, exploring data-driven technologies and strategies shaping the future of clinical trials. Dr. Rubin talks about the importance of optimism in patient care and his own clinical trial using...

Dr. David T. Rubin on “How I Treat Ulcerative Colitis”

by David Rubin | April 23, 2024 | In the Press, Presentations | 0 Comments

Dr. Rubin provides an in-depth look at the treatment of ulcerative colitis, from recent advances in therapeutic agents to setting patient expectations, positioning treatments, and monitoring for disease remission or progression. Click here for the full talk from the...

Dr. Rubin Taps in on “IBD Community Throwing Elbows Over Value of TDM” in Gastroenterology and Endoscopy News

by dtrubin | August 14, 2019 | In the Press, monitoring, therapies | 0 Comments

Dr. Mark Silverberg, Dr. David T Rubin, Dr. Laura Targownik, and Dr. Charabaty excitingly discuss why IBD specialists are divided on the topic of therapeutic drug monitoring (TDM). “If the drug is going to work but isn’t present in the body, it doesn’t do its job,”...

What Can We Do To Prevent COVID-19?

by tinar | June 7, 2021 | In the Press | 0 Comments

Click here for the full video discussing the use of COVID-19 vaccines to prevent COVID-19 infections in patients with inflammatory bowel disease.

Dr. David T. Rubin Hosts Pearls from the Pros on IBD Management

by David Rubin | March 1, 2022 | In the Press | 0 Comments

Dr. Rubin hosted four episodes of MedEd Talks Gastroenterology's Pearls from the Pros on IBD Management, featuring several colleagues to discuss best practices in using different classes of IBD therapies. Dr. Rubin spoke with Dr. Bruce Sands, Gastroenterologist and...

UChicago Medicine Patient First in the World to Receive Ulcerative Colitis Drug Since FDA Approval

by David Rubin | September 23, 2024 | In the Press | 0 Comments

A University of Chicago Medicine patient became the first person with ulcerative colitis in the world to receive the drug guselkumab (Tremfya) since its Sept. 11 approval by the FDA for treating moderate to severe ulcerative colitis. Tremfya has been used for many...

Improvements in Testing for SARS-CoV-2 and COVID-19 and How They Will Transform What we are Doing

by dtrubin | April 1, 2020 | Coronavirus, Rubin's Reflections | 0 Comments

By David T. Rubin, MD, Professor of Medicine, University of Chicago Medicine Here are some improvements in testing for SARS-COV-2 and COVID-19 and how I think they will transform what we are doing: 1. Faster Viral Tests for SARS-CoV-2. Several companies have adapted...

Message to Dr. Rubin’s Patients Related to COVID-19 Boosters

by David Rubin | August 13, 2021 | Rubin's Reflections | 0 Comments

Dr. Rubin featured on CME Outfitters “COVID-19 + IBD” Episode

by dtrubin | May 22, 2020 | In the Press | 0 Comments

The data on COVID-19 is changing rapidly and can be overwhelming. Having been on the frontlines of the pandemic, Dr. David T. Rubin, Dr. Sushila Dalal, and Dr. Miguel Regueiro break down the latest information and best practices for managing patients with IBD and...

Dr. Rubin Discusses Advances in Anti-Cytokine Therapy: The Current and Potential Role of IL-12/23 and IL-23 Inhibitors in the Treatment of IBD

by David Rubin | April 29, 2021 | In the Press | 0 Comments

Click here to watch Dr. Rubin discuss the advances in anti-cytokine therapy and receive AANP, AAPA, CME, CNE, CPE, or participation credit.